false
0000906709
0000906709
2026-09-24
2026-09-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 24, 2026
Nektar
Therapeutics
(Exact
name of registrant as specified in its charter)
| Delaware |
|
0-24006 |
|
94-3134940 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
455
Mission Bay Boulevard South
San
Francisco, California |
|
|
| |
94158 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (415) 482-5300
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
| Common
Stock, $0.0001 par value per share |
|
NKTR |
|
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
In August 2023, Nektar
Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District
Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach of contract and breach of the implied
covenant of good faith and fair dealing in connection with the license agreement governing the parties’ prior collaboration for
the development and commercialization of rezpegaldesleukin (the “License Agreement”). The case, Nektar Therapeutics v.
Eli Lilly & Co., Case No. 3:23-cv-03943-JD, proceeded to a jury trial beginning on September 8, 2026. On September 24, 2026, the
jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The
jury awarded the Company $90 million in damages plus interest to be determined by the District Court. The jury’s verdict remains
subject to post-trial proceedings, and any resulting judgment may be subject to appeal.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
NEKTAR
THERAPEUTICS |
| |
|
|
| Date:
September 25, 2026 |
By: |
/s/
Elizabeth Zhang |
| |
|
Elizabeth
Zhang
Vice President, Legal |
